The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

[1]  G. Garcia-Manero,et al.  Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results , 2023, American journal of hematology.

[2]  K. Davis,et al.  CD22 CAR T Cells Demonstrate Favorable Safety Profile and High Response Rates in Pediatric and Adult B-ALL: Results of a Phase 1b Study , 2022, Blood.

[3]  G. Garcia-Manero,et al.  Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. , 2022, The Lancet. Haematology.

[4]  E. Jabbour,et al.  Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review. , 2022, JAMA oncology.

[5]  L. Sehn,et al.  Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. , 2022, The Lancet. Oncology.

[6]  M. Loh,et al.  International Consensus Classification of Myeloid Neoplasms and Acute Leukemia: Integrating Morphological, Clinical, and Genomic Data. , 2022, Blood.

[7]  Y. Natkunam,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms , 2022, Leukemia.

[8]  H. Kantarjian,et al.  Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher , 2022, American journal of hematology.

[9]  S. Rives,et al.  S112: TISAGENLECLEUCEL IN PEDIATRIC AND YOUNG ADULT PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL): FINAL ANALYSES FROM THE ELIANA STUDY , 2022, HemaSphere.

[10]  T. Kadia,et al.  P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL) , 2022, HemaSphere.

[11]  T. Kadia,et al.  P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA , 2022, HemaSphere.

[12]  H. Kantarjian,et al.  A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL). , 2022, Journal of Clinical Oncology.

[13]  M. Konopleva,et al.  Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL). , 2022, Journal of Clinical Oncology.

[14]  G. Garcia-Manero,et al.  Intrathecal prophylaxis with 12 versus 8 administrations reduces the incidence of central nervous system relapse in patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia , 2022, American journal of hematology.

[15]  Hui Wang,et al.  Naturally Selected CD7 CAR-T Therapy without Genetic Manipulations for T-ALL/LBL: First-in-human Phase I Clinical Trial. , 2022, Blood.

[16]  He Huang,et al.  Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL , 2022, Blood.

[17]  Q. Rao,et al.  A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy , 2022, Experimental Hematology & Oncology.

[18]  M. Konopleva,et al.  Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab , 2022, American journal of hematology.

[19]  E. Jabbour,et al.  Clinical Value of Measurable Residual Disease in Acute Lymphoblastic Leukemia , 2022, Blood and lymphatic cancer : targets and therapy.

[20]  B. Wood,et al.  SWOG 1318: A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients With Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Harald J. Maier,et al.  Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia , 2021, Blood cancer discovery.

[22]  Snehit Prabhu,et al.  Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report , 2021, Journal of Clinical Oncology.

[23]  M. Konopleva,et al.  A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia , 2021, Blood.

[24]  D. Tichy,et al.  Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial , 2021, Blood.

[25]  G. Lenz,et al.  Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial) , 2021, Blood.

[26]  F. Pasquier,et al.  The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study , 2021, Blood.

[27]  E. Clappier,et al.  Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy Provides Very Good Outcome in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia: First Results from the EWALL-INO Study , 2021, Blood.

[28]  A. Wei,et al.  Sequential Blinatumomab with Reduced Intensity Chemotherapy in the Treatment of Older Adults with Newly Diagnosed Ph Negative B-Precursor Acute Lymphoblastic Leukemia - Interim Analysis of the Australasian Leukemia and Lymphoma Group ALL08 Study , 2021, Blood.

[29]  F. Pasquier,et al.  Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2 , 2021, Blood.

[30]  D. Leongamornlert,et al.  Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study , 2021, Leukemia.

[31]  R. Foà,et al.  INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia , 2021, Blood advances.

[32]  S. Grupp,et al.  CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials. , 2021, The Lancet. Haematology.

[33]  H. Kantarjian,et al.  Long-term outcome of hyper-CVAD-R for Burkitt leukemia/lymphoma and high-grade B-cell lymphoma: focus on CNS relapse , 2021, Blood advances.

[34]  K. Davis,et al.  CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial , 2021, Nature Medicine.

[35]  M. Konopleva,et al.  Impact of Philadelphia chromosome‐like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: A post hoc analysis from the phase 3 TOWER study , 2021, American journal of hematology.

[36]  M. Konopleva,et al.  Hyper‐CVAD plus ofatumumab versus hyper‐CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome–negative acute lymphoblastic leukemia: A propensity score analysis , 2021, Cancer.

[37]  R. Houot,et al.  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.

[38]  M. Konopleva,et al.  Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study. , 2021 .

[39]  M. Konopleva,et al.  Prognostic factors for progression in patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors , 2021, Cancer.

[40]  H. Kantarjian,et al.  Long‐term follow‐up of salvage therapy using a combination of inotuzumab ozogamicin and mini–hyper‐CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome–negative acute lymphoblastic leukemia , 2021, Cancer.

[41]  C. Pui,et al.  Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980–2017 , 2021, American journal of hematology.

[42]  M. Konopleva,et al.  Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine , 2021, American journal of hematology.

[43]  Chunxu Qu,et al.  Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. , 2021, Cancer discovery.

[44]  N. Shah,et al.  CAR T cells better than BiTEs. , 2021, Blood advances.

[45]  M. Relling,et al.  Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia , 2021, Nature Cancer.

[46]  M. Liedtke,et al.  Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia , 2020, Cancer.

[47]  M. Konopleva,et al.  Ultrasensitive Next-Generation Sequencing-Based Measurable Residual Disease Assessment in Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia after Frontline Therapy: Correlation with Flow Cytometry and Impact on Clinical Outcomes , 2020 .

[48]  M. Konopleva,et al.  Hyper-CVAD and Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia: Results from a Phase II Study , 2020 .

[49]  R. Advani,et al.  Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy , 2020 .

[50]  M. Konopleva,et al.  Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study , 2020 .

[51]  M. Konopleva,et al.  Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial , 2020 .

[52]  J. Esteve,et al.  Chemotherapy or Allogeneic Transplantation in High-Risk Philadelphia Chromosome-Negative Adult Lymphoblastic Leukemia. , 2020, Blood.

[53]  R. Foà,et al.  Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. , 2020, The New England journal of medicine.

[54]  M. Loh,et al.  Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Scott E. Smith,et al.  Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers. , 2020, Blood.

[56]  H. Dombret,et al.  Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia , 2020, Leukemia & lymphoma.

[57]  C. Mullighan,et al.  Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial. , 2020, The Lancet. Haematology.

[58]  S. Gupta,et al.  Cutting to the Front of the Line: Immunotherapy for Childhood Acute Lymphoblastic Leukemia. , 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[59]  H. Spencer,et al.  Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions , 2019, Journal of Hematology & Oncology.

[60]  Yiping Fan,et al.  Engineering Naturally Occurring CD7 Negative Cells for the Immunotherapy of CD7 Positive Leukemia , 2019, Blood.

[61]  M. Konopleva,et al.  Long-Term Safety and Efficacy of Hyper-CVAD Plus Ponatinib As Frontline Therapy for Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia , 2019, Blood.

[62]  Jeremy M. Stewart,et al.  A Multicenter Phase I Study Combining Venetoclax with Mini-Hyper-CVD in Older Adults with Untreated and Relapsed/Refractory Acute Lymphoblastic Leukemia , 2019, Blood.

[63]  H. Kantarjian,et al.  Title: 12 Versus 8 Prophylactic Intrathecal (IT) Chemotherapy Administration Decrease Incidence of Central Nervous System (CNS) Relapse in Patients (pts) with Newly Diagnosed Philadelphia (Ph)-Positive Acute Lymphocytic Leukemia (ALL) , 2019, Blood.

[64]  H. Dombret,et al.  Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia , 2019, Cancer.

[65]  M. Konopleva,et al.  The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia is a strong predictor for survival , 2019, American journal of hematology.

[66]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis , 2019, Cancer.

[67]  C. Bloomfield,et al.  A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. , 2019, Blood.

[68]  M. Liedtke,et al.  Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study , 2019, Cancer.

[69]  A. Logan,et al.  Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts , 2018, American journal of hematology.

[70]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. , 2018, The Lancet. Haematology.

[71]  J. Cayuela,et al.  Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02) , 2018, Blood.

[72]  H. Dombret,et al.  Blinatumomab for Minimal Residual Disease (MRD) in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Median Overall Survival (OS) Is Not Reached in Complete MRD Responders at a Median Follow-up of 53.1 Months , 2018, Blood.

[73]  K. Davis,et al.  Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia , 2018, Blood.

[74]  M. Konopleva,et al.  Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage , 2018, Cancer.

[75]  H. Dombret,et al.  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.

[76]  H. Kantarjian,et al.  Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front‐line Treatment of Newly Diagnosed Philadelphia‐positive Acute Lymphoblastic Leukemia , 2018, Clinical lymphoma, myeloma & leukemia.

[77]  M. Loh,et al.  Measurable residual disease detection by high-throughput sequencing improves risk stratification for pediatric B-ALL. , 2018, Blood.

[78]  M. Konopleva,et al.  Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[79]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[80]  R. Larson.  Managing CNS disease in adults with acute lymphoblastic leukemia , 2018, Leukemia & lymphoma.

[81]  M. Konopleva,et al.  Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial , 2017, JAMA oncology.

[82]  M. Konopleva,et al.  Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome‐positive Leukemia , 2017, Clinical lymphoma, myeloma & leukemia.

[83]  D. Dimitrov,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature medicine.

[84]  Ciaran M. Lee,et al.  CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. , 2017, Blood.

[85]  D. Berry,et al.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis , 2017, JAMA oncology.

[86]  H. Dombret,et al.  Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  M. Geyer,et al.  Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis. , 2017, Blood.

[88]  Sebastian Uhrig,et al.  Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia. , 2017, Blood.

[89]  W. Klapper,et al.  Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia , 2017, The New England journal of medicine.

[90]  C. Mullighan,et al.  Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. , 2017, Blood.

[91]  C. Bloomfield,et al.  High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[92]  M. Konopleva,et al.  Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome–negative acute lymphoblastic leukemia in the era of minimal residual disease , 2017, Cancer.

[93]  J. Radich,et al.  US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL. , 2016, Blood advances.

[94]  Shuling Li,et al.  Patient Characteristics and Treatment Patterns in Elderly Patients Newly Diagnosed with Acute Lymphoblastic Leukemia (ALL) Using 100% Medicare ALL Data , 2016 .

[95]  M. Konopleva,et al.  Hyper‐CVAD plus ponatinib versus hyper‐CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome‐positive acute lymphoblastic leukemia: A propensity score analysis , 2016, Cancer.

[96]  P. Houghton,et al.  Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. , 2016, Blood.

[97]  J. Cayuela,et al.  Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. , 2016, Blood.

[98]  G. Garcia-Manero,et al.  Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2016, Blood.

[99]  M. Liedtke,et al.  Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. , 2016, The New England journal of medicine.

[100]  G. Salles,et al.  Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial , 2016, The Lancet.

[101]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[102]  M. Konopleva,et al.  Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. , 2016, Blood.

[103]  D. Neuberg,et al.  Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remission , 2016, American journal of hematology.

[104]  Xuelin Huang,et al.  Minimal residual disease assessed by multi‐parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia , 2016, British journal of haematology.

[105]  R. Bassan.  Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  K. Coombes,et al.  MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199 , 2015, Cell reports.

[107]  R. Foà,et al.  Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification , 2015 .

[108]  Z. Estrov,et al.  Long‐term follow‐up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome–positive acute lymphoblastic leukemia , 2015, Cancer.

[109]  M. Konopleva,et al.  Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. , 2015, The Lancet. Oncology.

[110]  J. Cayuela,et al.  Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. , 2015, Blood.

[111]  M. Konopleva,et al.  Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia , 2015, Haematologica.

[112]  J. Bourhis,et al.  Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. , 2015, Blood.

[113]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[114]  Albrecht Reichle,et al.  Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Heather L. Mulder,et al.  Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. , 2014, The New England journal of medicine.

[116]  M. Loh,et al.  Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. , 2014, Cancer discovery.

[117]  A. Cortelezzi,et al.  Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia , 2014, Blood Cancer Journal.

[118]  A. Kohlmann,et al.  Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93% , 2014, Genes, chromosomes & cancer.

[119]  L. Staudt,et al.  Low-intensity therapy in adults with Burkitt's lymphoma. , 2013, The New England journal of medicine.

[120]  M. Kneba,et al.  Has MRD monitoring superseded other prognostic factors in adult ALL? , 2012, Blood.

[121]  E. Buss,et al.  Moderate Intensive Chemotherapy Including CNS-Prophylaxis with Liposomal Cytarabine Is Feasible and effective in Older Patients with Ph-Negative Acute Lymphoblastic Leukemia (ALL): Results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL) , 2012 .

[122]  H. Kantarjian,et al.  Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. , 2012, The Lancet Oncology.

[123]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[124]  R. Arceci.  The genetic basis of early T–cell precursor acute lymphoblastic leukaemia , 2012 .

[125]  R. Foà,et al.  Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. , 2011, Blood.

[126]  H. Kantarjian,et al.  First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. , 2010, Blood.

[127]  M. Andreeff,et al.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[128]  H. Kantarjian,et al.  Central nervous system prophylaxis in adults with acute lymphoblastic leukemia , 2010, Cancer.

[129]  Martin C. Müller,et al.  Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation. , 2009, Blood.

[130]  Cheng Cheng,et al.  Treating childhood acute lymphoblastic leukemia without cranial irradiation. , 2009, The New England journal of medicine.

[131]  W. Evans,et al.  A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. , 2009, The Lancet. Oncology.

[132]  Cheng Cheng,et al.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. , 2009, The Lancet. Oncology.

[133]  H. Kantarjian,et al.  Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia , 2008, Cancer.

[134]  H. Dombret,et al.  Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial , 2007, Leukemia.

[135]  R. Foà,et al.  Gruppo Italiano Malattie Ematologiche dell ' Adulto ( GIMEMA ) acute lymphoblastic leukemia without additional chemotherapy : results survival in elderly Philadelphia chromosome – positive patients with Imatinib plus steroids induces complete remissions and prolonged , 2007 .

[136]  Rajesh Chopra,et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. , 2007, Blood.

[137]  M. Andreeff,et al.  Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen as Frontline Therapy for Adult Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). , 2006 .

[138]  J. Sancho,et al.  Central nervous system recurrence in adult patients with acute lymphoblastic leukemia , 2006, Cancer.

[139]  H. Kantarjian,et al.  Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia , 2006, Cancer.

[140]  C. Pui.  Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. , 2006, Hematology. American Society of Hematology. Education Program.

[141]  M. Andreeff,et al.  Update of the Modified Hyper-CVAD Regimen with or without Rituximab in Newly Diagnosed Adult Acute Lymphocytic Leukemia (ALL). , 2005 .

[142]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[143]  J. Bourhis,et al.  Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial. , 2002, Blood.

[144]  M. Andreeff,et al.  Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[145]  X. Thomas,et al.  Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. , 1998, Hematology and cell therapy.

[146]  N. Chao,et al.  Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia [letter] , 1995 .

[147]  N. Chao,et al.  Long-term follow-up of allogeneic bone marrow recipients for Philadelphia chromosome-positive acute lymphoblastic leukemia. , 1995, Blood.

[148]  H. Kantarjian,et al.  Management of adult acute lymphocytic leukemia: present issues and key challenges. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.